Real-time immunohistochemistry analysis of embedded tissue.

We present a novel analysis of membrane-protein expression in tissue sections based on semi-automatic real-time measurement using LigandTracer(®) technology. A commercial antiHER2 antibody developed for immunohistochemistry used in this setup was revealed to have sub-optimal interaction with tissue when analyzed as recommended for immunohistochemistry. We therefore think that real-time measurement of tissue, offering direct and quantitative membrane-protein interaction analysis, can lead to improved reproducibility and eliminate the subjective operator dependences that classical immunohistochemsitry suffers from.

[1]  Karl Andersson,et al.  Automated, high-resolution cellular retention and uptake studies in vitro. , 2006, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[2]  A. Dueñas-González,et al.  Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer. , 2006, Cancer treatment reviews.

[3]  A. Vincent-Salomon,et al.  Re: HER2 testing in the real world. , 2003, Journal of the National Cancer Institute.

[4]  R. Bast,et al.  Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. , 1998, Hybridoma.

[5]  K. Wester,et al.  Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases , 2005, BJU international.

[6]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[7]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.

[8]  Gloria Bueno,et al.  Review of imaging solutions for integrated quantitative immunohistochemistry in the Pathology daily practice. , 2010, Folia histochemica et cytobiologica.

[9]  Mark M Davis,et al.  How T cells 'see' antigen , 2005, Nature Immunology.

[10]  L. Huo.  HER2 Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial , 2007 .

[11]  F. Schmitt,et al.  HER2+ breast cancer: How to evaluate? , 2009, Advances in therapy.

[12]  Jorma Isola,et al.  Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.